scholarly journals The autonomic nervous system and ventricular arrhythmias in myocardial infarction and heart failure

2020 ◽  
Vol 43 (2) ◽  
pp. 172-180 ◽  
Author(s):  
Perry Wu ◽  
Marmar Vaseghi
2014 ◽  
Vol 3 (1) ◽  
pp. 30-35 ◽  
Author(s):  
William J Hucker ◽  
Jagmeet P Singh ◽  
Kimberly Parks ◽  
Antonis A Armoundas

Alterations in resting autonomic tone can be pathogenic in many cardiovascular disease states, such as heart failure and hypertension. Indeed, autonomic modulation by way of beta-blockade is a standard treatment of these conditions. There is a significant interest in developing non-pharmacological methods of autonomic modulation as well. For instance, clinical trials of vagal stimulation and spinal cord stimulation in the treatment of heart failure are currently underway, and renal denervation has been studied recently in the treatment of resistant hypertension. Notably, autonomic stimulation is also a potent modulator of cardiac electrophysiology. Manipulating the autonomic nervous system in studies designed to treat heart failure and hypertension have revealed that autonomic modulation may have a role in the treatment of common atrial and ventricular arrhythmias as well. Experimental data on vagal nerve and spinal cord stimulation suggest that each technique may reduce ventricular arrhythmias. Similarly, renal denervation may play a role in the treatment of atrial fibrillation, as well as in controlling refractory ventricular arrhythmias. In this review, we present the current experimental and clinical data on the effect of these therapeutic modalities on cardiac electrophysiology and their potential role in arrhythmia management.


ESC CardioMed ◽  
2018 ◽  
pp. 173-180
Author(s):  
Atul Pathak

Drugs able to modulate the autonomic nervous system have improved the outcome of many cardiovascular and non-cardiovascular conditions. In particular, heart failure, post-myocardial infarction, and hypertension are the cardiovascular clinical syndromes in which autonomic nervous system inhibition or stimulation has modified patient outcomes. While in heart failure and post-myocardial infarctions beta blockers have become a cornerstone therapy by improvement of morbidity and mortality, their use in hypertension has been progressively limited. The same is true for other drugs modulating the autonomic nervous system such as alpha blockers, used only in patients with difficult to control hypertension and not in heart failure patients, in whom this class of drugs exacerbates heart failure in clinical trials. This chapter aims to provide an appraisal of drugs modulating the autonomic nervous system with descriptions of their mechanism(s) of action, pharmacokinetics, adverse effects, and drug interactions.


1994 ◽  
Vol 24 (2) ◽  
pp. 272 ◽  
Author(s):  
Ji Won Park ◽  
Ho Joong Youn ◽  
Wook Sung Chung ◽  
Joon Chul Park ◽  
Chul Min Kim ◽  
...  

2020 ◽  
Vol 9 (5) ◽  
pp. 1481 ◽  
Author(s):  
Audrey Sagnard ◽  
Charles Guenancia ◽  
Basile Mouhat ◽  
Maud Maza ◽  
Marie Fichot ◽  
...  

Background: Atrial fibrillation (AF) is common after acute myocardial infarction (AMI) and associated with in-hospital and long-term mortality. However, the pathophysiology of AF in AMI is poorly understood. Heart rate variability (HRV), measured by Holter-ECG, reflects cardiovascular response to the autonomic nervous system and altered (reduced or enhanced) HRV may have a major role in the onset of AF in AMI patients. Objective: We investigated the relationship between autonomic dysregulation and new-onset AF during AMI. Methods: As part of the RICO survey, all consecutive patients hospitalized for AMI at Dijon (France) university hospital between June 2001 and November 2014 were analyzed by Holter-ECG <24 h following admission. HRV was measured using temporal and spectral analysis. Results: Among the 2040 included patients, 168 (8.2%) developed AF during AMI. Compared to the sinus-rhythm (SR) group, AF patients were older, had more frequent hypertension and lower left ventricular ejection fraction LVEF. On the Holter parameters, AF patients had higher pNN50 values (11% vs. 4%, p < 0.001) and median LH/HF ratio, a reflection of sympathovagal balance, was significantly lower in the AF group (0.88 vs 2.75 p < 0.001). The optimal LF/HF cut-off for AF prediction was 1.735. In multivariate analyses, low LF/HF <1.735 (OR(95%CI) = 3.377 (2.047–5.572)) was strongly associated with AF, ahead of age (OR(95%CI) = 1.04(1.01–1.06)), mean sinus-rhythm rate (OR(95%CI) = 1.03(1.02–1.05)) and log NT-proBNP (OR(95%CI) = 1.38(1.01–1.90). Conclusion: Our study strongly suggests that new-onset AF in AMI mainly occurs in a dysregulated autonomic nervous system, as suggested by low LF/HF, and higher PNN50 and RMSSD values.


Sign in / Sign up

Export Citation Format

Share Document